lilly glp 1 small molecule GLP-1 agonists Eli Lilly Announces Successful Phase

This long game means lifestyle education and the ongoing bolstering of behavior change, which is bloody hard but do-able if we employ smart, clever, insightful design teams who deeply understand whats underneath patients lives and daily choices

Understanding your state's specific policy, clinical criteria, and biomarker context can help guide personalized treatme

On the flipside, there are challenges: for example, concerns about cost to healthcare systems and equity of access for patients with the greatest unmet needs, or the possible impact on Medtech currently used by patients suffering from obesity related conditions for example knee replacements for overweight patients with eroded joints or CPAP machines for sleep apnoea, a complication of obesity

An extensive breakdown of exactly why the GLP-1 hype is making people with eating disorder/weight stigma histories feel like they can't trust themselves.

What they found was cost dominates treatment decisions: 68% said cost influenced their decision to start or continue treatment 44% said the medication cost more than they expected Cost surpassed side effects as the #1 reason people stopped taking GLP-1s A breakdown of the financial burden: 24% pay more than $250 per prescription fill Nearly 8% pay $500 or more per fill 24% said insurance didn't cover any cost Weight management patients were nearly twice as likely to pay $250+ vs diabetes patients --- Here's what patients are thinking: Nearly 40% ended up using discount programs or manufacturer coupons 60% know someone who wants GLP-1s but can't afford them 83% believe Americans turn to DTC programs because traditional healthcare is too expensive Patients still prioritize safety: 60% are aware of safety risks with non-FDA-approved GLP-1s--this one surprised me

Lasting results with medical support